Institutional investors with REGN positions may need to assess alleged clinical-trial disclosure failures that preceded a $102.09 per-share decline from the Class Period high. This notice focuses on fiduciary review, portfolio loss documentation, and lead plaintiff considerations.NEW YORK, Aug. 6…
Revenue grew 17% and non-GAAP EPS rose 11% year-over-year, driven by record sales of Dupixent, EYLEA HD, and Libtayo. The pipeline remains robust with multiple regulatory milestones ahead, and capital allocation continues to prioritize internal R&D and disciplined external opportunities.Based on Re…
Double-digit revenue and EPS growth were driven by record sales of Dupixent, EYLEA HD, and Libtayo, with robust pipeline progress and strong cash flow supporting continued R&D and share repurchases. Key regulatory milestones are expected for cemdisiran and garetosmab, while EYLEA HD and Dupixent ma…
Q2 2026 revenues rose 17% year-over-year to $4.29B, driven by Dupixent and Libtayo, while EYLEA sales declined due to biosimilar competition. Net income was $1.30B with EPS of $12.23. The company faces ongoing pricing, regulatory, and competitive pressures, but maintains a strong pipeline and robus…
Q2 2026 revenues rose 17% to $4.3B, led by record sales of Dupixent, EYLEA HD, and Libtayo. Non-GAAP EPS grew 11% to $14.29, and the Sanofi Development Balance was fully repaid, boosting future collaboration profits. Regulatory and pipeline progress continued.Original document: Regeneron Pharmaceut…
Biotech company Regeneron NASDAQ:REGNwill be reporting results this Thursday before the bell. Here’s what you need to know.Regeneron beat analysts’ revenue expectations last quarter, reporting revenues of $3.61 billion, up 19% year on year. It was a very strong quarter for the company, with a beat…
Regeneron's clinical-trial risk disclosures are under scrutiny after allegations that the Company minimized Phase III Fianlimab-Libtayo statistical and protocol risks, including potential impact of FDA Otptimus-related amendments on progression-free survival analysis.NEW YORK, July 23, 2026 /PRNews…
MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX:TLX, NASDAQ:TLX, "Telix") provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026).Q2 2026 Highlights[1]Q2 2026 RevenueExecutive Commen…
(10:47 GMT) Regeneron Pharma Price Target Announced at $185.00/Share by Benchmark
(13:01 GMT) Regeneron Pharma Price Target Cut to $750.00/Share From $785.00 by Cantor Fitzgerald
